<html>
<head>
<title>ACP</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>

<body bgcolor="B6b6b6">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="214d7b" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><a name="Top"></a><img src="../Assets/HFACEtitle.gif" width="430" height="50"></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_HFandACE.html"><img src="../Assets/ACP1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_HFandACE.html"><img src="../Assets/ACP2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_HFandACE.html"><img src="../Assets/ACP3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_HFandACE.html"><img src="../Assets/ACP4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_HFandACE.html"><img src="../Assets/ACP5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_HFandACE.html"><img src="../Assets/ACP6.gif" width="121" height="37" border="0"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/ACPheader.gif" width="330" height="50" align="baseline"><img src="../Assets/ACPheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="746" height="469" bgcolor="ffffff"> 
            <div align="center"><br>
              <table width="90%" border="0">
                <tr> 
                  <td colspan="2"> <p class="BEsection"><font color="#3399CC">Therapeutics</font></p>
                    <table width="100%" border="0">
                      <tr> 
                        <td bgcolor="#6699CC"><a name="diureticsreducedcardiovasculardiseaseeventsindiabeticandnondiabeticpatients"></a><font size="4"><strong>High-dose 
                          lisinopril was more effective than low-dose for reducing 
                          combined mortality and cardiovascular events in CHF</strong></font></td>
                      </tr>
                    </table>
                    <P CLASS="ACPSource">ACP Journal Club. 2000 July-Aug;133:4.<BR>
                    </p>
                    <P CLASS="Citation">Packer M, Poole-Wilson PA, Armstrong PW, 
                      et al., on behalf of the ATLAS Study Group. <b>Comparative 
                      effects of low and high doses of the angiotensin-converting 
                      enzyme inhibitor, lisinopril, on morbidity and mortality 
                      in chronic heart failure.</b> Circulation. 1999 Dec 7;100:2312-8. 
                    </p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="AbsHd"><font color="#3399CC">Question</font></p>
                    <P CLASS="AbsTxt">In patients with congestive heart failure 
                      (CHF), is high-dose lisinopril more effective than low-dose 
                      lisinopril for reducing mortality and hospitalization rates? 
                    </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Design</font></p>
                    <P CLASS="AbsTxt">Randomized (allocation concealment unclear*), 
                      blinded (patients, investigators, and outcome assessors),* 
                      controlled trial with 3-year follow-up. </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Setting</font></p>
                    <P CLASS="AbsTxt">287 hospitals in 19 countries.</p>
                    <P CLASS="AbsHd"><font color="#3399CC">Patients</font></p>
                    <P CLASS="AbsTxt">3793 patients were screened, and 3164 (mean 
                      age 63.6 y, 80% men) were studied. Inclusion criteria were 
                      New York Heart Association class II, III, or IV CHF, despite 
                      use of diuretics for 2 months, and left ventricular ejection 
                      fraction 30%. Exclusion criteria were recent revascularization 
                      procedure or ischemic event, history of ventricular tachycardia, 
                      intolerance to angiotensin-converting enzyme (ACE) inhibitors, 
                      serum creatinine levels &gt; 2.5 mg/dL, or noncardiac disorders 
                      that could limit survival. Follow-up was 100%. </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Intervention</font></p>
                    <P CLASS="AbsTxt">Patients received their usual CHF medications 
                      and were allocated to lisinopril, 2.5 or 5.0 mg/d (n = 1596), 
                      or 30 mg/d (n = 1568). </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Main outcome measures</font></p>
                    <P CLASS="AbsTxt">All-cause mortality. Secondary end points 
                      were cardiovascular (CV) mortality and 5 combined end points.</p>
                    <P CLASS="AbsHd"><font color="#3399CC">Main results</font></p>
                    <P CLASS="AbsTxt">The groups did not differ for all-cause 
                      mortality (42.5% for high-dose vs 44.9% for low-dose lisinopril, 
                      P = 0.13) or CV mortality (37.2% vs 40.2%, P = 0.07). Patients 
                      in the high-dose group had lower rates of all-cause mortality 
                      combined with all-cause hospitalization (P = 0.002), CV 
                      hospitalization (P = 0.04), or CHF hospitalization (P &lt; 
                      0.001) and lower rates of CV mortality plus CV hospitalization 
                      (P = 0.03) (Table) than did patients in the low-dose lisinopril 
                      group. </p>
                    <P CLASS="AbsHd"><font color="#3399CC">Conclusion</font></p>
                    <P CLASS="AbsTxt">High-dose lisinopril was more effective 
                      than low-dose lisinopril for reducing the combined end points 
                      of all-cause mortality combined with either all hospitalization, 
                      CV hospitalization, or CHF hospitalization and CV mortality 
                      plus CV hospitalization for patients with CHF. </p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="Grant">Source of funding: 
                      Zeneca Pharmaceuticals.</p>
                    <P CLASS="Grant">For correspondence: Dr. M. Packer, Division 
                      of Circulatory Physiology, Columbia University College of 
                      Physicians and Surgeons, 630 West 168th Street, New York, 
                      NY 10032, USA. FAX 212-305-7439. </p>
                    <P CLASS="Reprint">*See <a href="../Assets/Glossary2.html">Glossary</a>.</p>
                    <HR SIZE=2 COLOR=#3399CC> <P CLASS="CmHd"><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">High-dose 
                      vs low-dose lisinopril for congestive heart failure (CHF)â€ </font></p>
                    <table border=0 cellpadding=3 cellspacing=0 width="100%">
                      <tbody>
                        <tr valign=top> 
                          <th class=colhdl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Outcomes 
                            at 3 y </font></th>
                          <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">High-dose 
                            </font></th>
                          <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Low-dose 
                            </font></th>
                          <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Hazard 
                            ratio (95% CI) </font></th>
                          <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">NNT 
                            (CI) </font></th>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Mortality 
                            plus hospitalization </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">79.7% 
                            </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">83.8% 
                            </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">0.88 
                            (0.82 to 0.96) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">26 
                            (16 to 82) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Mortality 
                            plus CV hospitalization </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">71.1% 
                            </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">74.1% 
                            </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">0.92 
                            (0.84 to 0.99) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">34 
                            (17 to 284) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Mortality 
                            plus CHF hospitalization </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">55.1% 
                            </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">60.4% 
                            </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">0.85 
                            (0.78 to 0.93) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">17 
                            (12 to 37) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                        <tr valign=top> 
                          <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">CV 
                            mortality plus CV hospitalization </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">69.4% 
                            </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">72.7% 
                            </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">0.91 
                            (0.84 to 0.99) </font></td>
                          <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">30 
                            (16 to 281) </font></td>
                        </tr>
                        <tr> 
                          <td colspan=99 height=1> <hr noShade size=1> </td>
                        </tr>
                      </tbody>
                    </table>
                    <p> 
                    <P CLASS="Reprint">†CV = cardiovascular. Other abbreviations 
                      defined in <a href="../Assets/Glossary2.html">Glossary</a>; 
                      NNT and its CI calculated by using hazard ratios provided 
                      in article. </p>
                    <hr size=2 color=#3399CC> <P CLASS="AbsHd"><font color="#3399CC">Commentary</font></p>
                    <P CLASS="CmTxt">Large randomized controlled trials (RCTs) 
                      have shown that high-dose ACE inhibitors are generally safe 
                      in CHF. Many clinicians remain concerned, however, about 
                      safety issues and resort to the use of low-dose ACE inhibitors. 
                      The Assessment of Treatment with Lisinopril and Survival 
                      (ATLAS) trial is the largest RCT comparing a high- and low-dose 
                      ACE inhibitor in CHF. The results show a trend toward decreased 
                      mortality and a modest reduction in combined end points 
                      that include hospitalization and mortality. This finding 
                      is somewhat surprising because a larger benefit with high-dose 
                      ACE inhibitors was anticipated. The only other RCT that 
                      evaluated a low- and high-dose ACE-inhibitor strategy in 
                      CHF was too small and too short to provide clear answers 
                      (1). Although the benefits in the ATLAS study seem relatively 
                      modest, morbidity that includes hospitalization is a major 
                      consideration in CHF, both from the patient's and the clinician's 
                      perspective. </p>
                    <P CLASS="CmTxt">How are clinicians to interpret the results 
                      of the ATLAS trial? First, the use of ACE inhibitors is 
                      well established as first-line therapy in CHF, and every 
                      patient with clinical manifestations or with asymptomatic 
                      left ventricular systolic dysfunction should be considered 
                      for ACE-inhibitor therapy. Therapy should be initiated with 
                      caution, however, especially in elderly patients and in 
                      those with renal dysfunction or low blood pressure. Patients 
                      should be followed with careful and gradual increases in 
                      dose. If the drug is tolerated, an attempt should be made 
                      to maximize the ACE inhibitor dose. If side effects develop, 
                      however, maintaining patients on a low or intermediate dose 
                      is far better than withdrawing therapy. In addition, as 
                      suggested by the ATLAS study and many previous investigations, 
                      such symptoms as cough, hypotension, dizziness, and renal 
                      dysfunction are not always related to ACE inhibitor use 
                      and may be caused by CHF, concomitant illnesses, or other 
                      medications. Permanent withdrawal of ACE inhibitors should 
                      be a last resort and considered only in patients who clearly 
                      cannot tolerate this lifesaving intervention. </p>
                    <P CLASS="CmTxt">In addition, as suggested by the ATLAS study 
                      and many previous investigations, such symptoms as cough, 
                      hypotension, dizziness, and renal dysfunction are not always 
                      related to ACE inhibitor use and may be caused by CHF, concomitant 
                      illnesses, or other medications. Permanent withdrawal of 
                      ACE inhibitors should be a last resort and considered only 
                      in patients who clearly cannot tolerate this lifesaving 
                      intervention. </p>
                    <P CLASS="CmTxt"><b>Eva Lonn, MD</b><BR>
                      Hamilton General Hospital McMaster Clinic<BR>
                      Hamilton, Ontario, Canada</p>
                    <HR SIZE=2 COLOR=#3399CC> <br> <table width="100%" border="0">
                      <tr> 
                        <td bgcolor="#6699CC"><strong>Reference</strong></td>
                      </tr>
                    </table>
                    <P CLASS="CmRef"><b>1.</b> <i>The NETWORK Investigators.</i> 
                      <b>Clinical outcome with enalapril in symptomatic chronic 
                      heart failure: a dose comparison.</b> Eur Heart J. 1998;19:481-9. 
                    </p>
                    <p></p>
                    <p class="CmRef" align="right">&nbsp;</p></td>
                </tr>
                <tr> 
                  <td width="88%"><div align="center"><strong>Reprinted with permission<br>
                      &copy; American College of Physicians- American Society 
                      of Internal Medicine</strong></div></td>
                  <td width="12%"><div align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></div></td>
                </tr>
              </table>
              <p class="BEsection" align="right">&nbsp;</p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="528ece"> 
          
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
